Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more
Arovella Therapeutics Ltd - Asset Resilience Ratio
Arovella Therapeutics Ltd (ALA) has an Asset Resilience Ratio of 96.65% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Arovella Therapeutics Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Arovella Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$20.88 Million | 96.65% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$20.88 Million | 96.65% |
Asset Resilience Insights
- Very High Liquidity: Arovella Therapeutics Ltd maintains exceptional liquid asset reserves at 96.65% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Arovella Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Arovella Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Arovella Therapeutics Ltd (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Arovella Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 96.65% | AU$20.88 Million | AU$21.60 Million | +0.95pp |
| 2024-06-30 | 95.71% | AU$12.71 Million | AU$13.28 Million | +1.11pp |
| 2023-06-30 | 94.60% | AU$5.18 Million | AU$5.47 Million | +28.70pp |
| 2022-06-30 | 65.90% | AU$6.07 Million | AU$9.21 Million | +3.05pp |
| 2021-06-30 | 62.85% | AU$6.72 Million | AU$10.69 Million | +48.28pp |
| 2020-06-30 | 14.57% | AU$977.47K | AU$6.71 Million | -11.97pp |
| 2019-06-30 | 26.54% | AU$4.31 Million | AU$16.25 Million | +25.95pp |
| 2018-06-30 | 0.59% | AU$98.13K | AU$16.64 Million | -8.25pp |
| 2017-06-30 | 8.84% | AU$1.77 Million | AU$20.02 Million | +8.13pp |
| 2009-06-30 | 0.71% | AU$118.52K | AU$16.61 Million | -0.01pp |
| 2008-06-30 | 0.73% | AU$116.62K | AU$16.06 Million | -8.25pp |
| 2007-06-30 | 8.98% | AU$1.89 Million | AU$21.00 Million | +1.64pp |
| 2006-06-30 | 7.34% | AU$1.22 Million | AU$16.63 Million | -- |